COVID-19: How Well Have The Vaccine Makers Performed?

Follow us on Google News:
 COVID-19: How Well Have The Vaccine Makers Performed?

Source:Dimitris Barletis ,Shutterstock

There are currently four major vaccines rolling out around the world. Some of these vaccines have been developed by companies that are listed on exchanges. The amount of business these companies are doing right now is pretty phenomenal. Billions of vaccines are being made in a very short period, helping to boost the books of these companies.

Source: Copyright © 2021 Kalkine Media Pty Ltd

Let us take a look at how some of these companies have moved across the market.

AstraZeneca-Oxford Vaccine

AstraZeneca plc (LON:AZN) is a British-Swedish biopharmaceutical company based out of Cambridge, England. The University of Oxford is also based out of Cambridge, and so a collaborative partnership that produced the two-shot AstraZeneca-Oxford vaccine materialised.

Source: Copyright © 2021 Kalkine Media Pty Ltd

The stock price of AstraZeneca shot up in 2020, before incrementally shifting down a few gears. The Company’s stock rose to a high of GBX 9,320 (closing price) in July 2020 before pulling back down to where it sits today. In the past 52 weeks, the Company’s stock has risen by 12.3%.

On 15 March, by the end of the trading session, AstraZeneca shares quoted GBX 6,988.29, increasing by 0.54%.

Pfizer-BioNTech Vaccine

Pfizer Inc (NYSE:PFE) collaborated with BioNTech SE - ADR (NASDAQ:BNTX) to produce the Pfizer-BioNTech Vaccine. Pfizer is a US-based pharmaceutical company, while BioNTech is a German clinical-stage medicine assessor.

Pfizer’s stock has performed well over the past year, up by 23.9%. Also, BioNTech’s stock performance is a standout among the vaccine producers, rising by 169.7% over the year.

On 15 March, Pfizer shares last traded at US$35.41, increasing by 1.37%. On the same day, BioNTech shares ended at US$107.88, increasing by 4.45%.

Moderna Vaccine

Moderna Inc (NASDAQ:MRNA) is a US pharmaceutical company that develop drugs and vaccines. The Moderna vaccine did not come from a partnership like the vaccines mentioned above.

However, Moderna has recently announced a strategic alliance with the Swiss drug manufacturer, Lonza Group AG (SWX:LONN). Lonza will start creating the ingredients used in the Moderna vaccine to speed up vaccine production.

 Source: Copyright © 2021 Kalkine Media Pty Ltd

Moderna’s stock price has risen the most out of the vaccine producing companies over the past year. Since 16 March 2020, Moderna is up by 442%.

On 15 March, at the time of writing, Moderna shares last traded at US$143.66, increasing 4.87%. While Lonza ended the market session at CHF544.00, decreasing by 0.37%.

Johnson & Johnson Vaccine

Johnson & Johnson (NYSE:JNJ) is a US manufacturer that produces a wide variety of consumer and health products. The Company also has a medical device and biopharmaceutical segment.

Johnson & Johnson’s vaccine is the only one of the four detailed here that is a single shot. However, the efficacy of the vaccine is far less than the others.

Source: © Terovesalainen |

Johnson & Johnson stock price has risen by 26.2% in the past 52 weeks. Much of the rise came in March and April of 2020, after the announced pre-trial success of its vaccine.

On 15 March, Johnson & Johnson shares last traded at US$160.42, increasing 0.51%.

READ MORE: EU faces AstraZeneca’s COVID-19 vaccine shortage amid manufacturing concerns


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK